文献速递心脑血管急症消化、代谢与肾脏急症

稳定型心肌梗死后射血分数保留且无心力衰竭患者停用β受体阻滞剂:个体患者数据汇总分析

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
PubMed 文献 · Lancet · 2026-08-30
一句话结论心肌梗死后左室射血分数≥40%、无心力衰竭且无其他适应证的稳定患者,停用β受体阻滞剂在主要复合终点和关键次要终点上达到非劣效标准。

该研究汇总了ABYSS和SMART-DECISION两项随机试验的个体患者数据,纳入心肌梗死后超过6个月、左室射血分数≥40%、无心力衰竭的稳定患者6238例(停用组3092例,继续组3146例),中位随访3.0年。主要复合终点(全因死亡、心肌梗死、卒中或心血管原因住院)停用组17.2% vs 继续组15.9%(HR 1.09,95%CI 0.97-1.24),非劣效性P=0.016;关键次要终点(全因死亡、心肌梗死或心力衰竭住院)停用组6.5% vs 继续组6.4%(HR 1.01,95%CI 0.83-1.23),非劣效性P=0.0006。结果在不同基线左室射血分数下一致。作者指出主要终点解读受其住院占比高和试验依赖性构成限制。

要点

  • 心肌梗死后>6个月、LVEF≥40%、无心力衰竭且无其他β受体阻滞剂适应证的稳定患者,停用β受体阻滞剂主要复合终点达非劣效(HR 1.09,95%CI 0.97-1.24,非劣效P=0.016)。
  • 关键次要终点(全因死亡、心肌梗死或心力衰竭住院)停用组6.5% vs 继续组6.4%(HR 1.01,95%CI 0.83-1.23,非劣效P=0.0006)。
  • 停用与继续β受体阻滞剂的结果在不同基线左室射血分数下一致。
  • 主要终点组成以住院为主且依赖试验设计,作者指出其解读受限。

适用人群与场景

  • 心肌梗死后超过6个月的稳定患者,左室射血分数≥40%,无心力衰竭,且无其他β受体阻滞剂治疗适应证。
  • 来源于ABYSS和SMART-DECISION两项随机试验的个体患者数据。

研究设计与关键结果

  • 汇总分析纳入6238例患者(ABYSS 3698例,SMART-DECISION 2540例),停用β受体阻滞剂组3092例,继续组3146例。
  • 从指数心肌梗死到随机化的中位时间为3.6年(IQR 1.6-7.5),中位随访3.0年(IQR 2.3-3.8)。
  • 主要复合终点(全因死亡、心肌梗死、卒中或心血管原因住院)停用组532/3092例(17.2%)vs 继续组500/3146例(15.9%),HR 1.09(95%CI 0.97-1.24),非劣效性P=0.016。
  • 关键次要终点(全因死亡、心肌梗死或心力衰竭住院)停用组201/3092例(6.5%)vs 继续组201/3146例(6.4%),HR 1.01(95%CI 0.83-1.23),非劣效性P=0.0006。
  • 结果在不同基线左室射血分数下一致。

证据类型、等级与局限

  • 证据类型:ABYSS和SMART-DECISION两项随机试验个体患者数据的汇总分析。
  • 非劣效性界值:主要终点为1.25,关键次要终点为1.40。
  • 局限:主要终点组成以住院为主且依赖试验设计,作者指出其解读受限。

对床旁实践的改变

  • 对于心肌梗死后超过6个月、左室射血分数≥40%、无心力衰竭且无其他β受体阻滞剂适应证的稳定患者,停用β受体阻滞剂在主要复合终点和关键次要终点上达到非劣效标准。
  • 作者指出主要终点解读受其住院占比高和试验依赖性构成限制。

指南或共识出处

  • 研究方案已在PROSPERO注册,注册号CRD420261299839。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Many stable patients with chronic coronary syndrome continue β-blocker therapy for years after a myocardial infarction, despite having no clear ongoing indication. Whether β-blockers can be safely discontinued in such patients remains uncertain. The objective of this analysis was to assess the non-inferiority of β-blocker discontinuation versus continuation in patients with previous myocardial infarction and no remaining indication.

METHODS: We performed a pooled analysis of individual patient data from the ABYSS and SMART-DECISION randomised trials in stable patients over 6 months after a myocardial infarction with a left ventricular ejection fraction of ≥40% and no heart failure. Non-inferiority was assessed for the composite primary endpoint of all-cause death, myocardial infarction, stroke, or hospitalisation for cardiovascular reasons, and for the key secondary endpoint of all-cause death, myocardial infarction, or hospitalisation for heart failure. Analyses used a one-stage mixed-effects Cox proportional hazards model including trial as a random effect with margins of 1·25 for the primary endpoint and 1·40 for the key secondary endpoint. The review protocol was registered with PROSPERO, number CRD420261299839.

FINDINGS: Among 6238 patients (3698 from ABYSS and 2540 from SMART-DECISION), 3092 were assigned to β-blocker discontinuation and 3146 to continuation. Median time from index myocardial infarction to randomisation was 3·6 years (IQR 1·6-7·5) and median follow-up was 3·0 years (2·3-3·8). The primary endpoint occurred in 532 (17·2%) of 3092 patients in the β-blocker discontinuation group and 500 (15·9%) of 3146 in the continuation group (hazard ratio 1·09 [95% CI 0·97-1·24]; pnon-inferiority=0·016). The key secondary endpoint occurred in 201 (6·5%) of 3092 patients in the discontinuation group and 201 (6·4%) of 3146 patients in the continuation group (1·01 [0·83-1·23]; pnon-inferiority=0·0006). Findings were consistent irrespective of background left ventricular ejection fraction.

INTERPRETATION: In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints. Interpretation of the primary endpoint is limited by its hospitalisation-heavy and trial-dependent composition.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Silvain J, Choi KH, Monguillon V, et al. Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data. Lancet. 2026. PMID: 42669300. doi:10.1016/S0140-6736(26)01426-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。